Progress in Hodgkin lymphoma: A population-based study on patients diagnosed in Sweden from 1973-2009

Blood

Volumn 119, Issue 4, 2012, Pages 990-996

  Sjöberg, Jan ^a   Halthur, Cat ^b   Kristinsson, Sigurdur Y ^a   Landgren, Ola ^a,c   Nygell, Ulla Axdorph ^a   Dickman, Paul W ^b   Björkholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SWEDEN;

EID: 84856274205     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-302604     Document Type: Article

References (51)

1. Klimm B, Schnell R, Diehl V, et al. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica. 2005;90(12):1680-1692. (Pubitemid 41818990)
2. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548-4554.
3. Björkholm M, Holm G, Mellstedt H. Immunocompetence in patients with Hodgkin's disease. In: Lacher M, Redman J, eds. Consequences of Survival in Hodgkin's Disease. New York, NY: Lea & Febiger; 1990:112-150.
4. van Leeuwen FE, Chorus AM, van den Belt- Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12(5):1063-1073.
5. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8 Suppl 1:115-118.
6. Salloum E, Jillella AP, Nadkarni R, et al. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer. 1998;82(8):1506-1512. (Pubitemid 28164997)
7. van Leeuwen F, Swerdlow A, Valagussa P, et al. Second cancers after treatment of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, et al, eds. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:607-632.
8. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol. 2000;18(3):498-509. (Pubitemid 30078531)
9. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108. (Pubitemid 34408801)
10. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-3439. (Pubitemid 46603515)
11. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22(15):3139-3148. (Pubitemid 41103728)
12. Landgren O, Björkholm M, Konradsen H, et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Internal Med. 2004;255(6):664-673. (Pubitemid 38703585)
13. Chow LM, Nathan PC, Hodgson DC, et al. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and lowdose, extended-field irradiation. J Clin Oncol. 2006;24(36):5735-5741.
14. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
15. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007;25(1):43-49. (Pubitemid 350003049)
16. De Bruin ML, Dorresteijn LDA, van't Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101(13):928-937.
17. Wettergren L, Björkholm M, Axdorph U, et al. Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. Qual Life Res. 2004;13(8):1369-1379. (Pubitemid 39221624)
18. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305-313. (Pubitemid 15028463)
19. Barlow L, Westergren K, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33.
20. Axdorph U, Porwit-Macdonald A, Sjöberg J, Grimfors G, Björkholm M. T- cell-rich B-cell lymphoma - diagnostic and therapeutic aspects. APMIS. 2002;110(5):379-390. (Pubitemid 34666553)
21. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer. 2007;121(10):2260-2266. (Pubitemid 47585607)
22. Devita VT Jr, Serpick AA, Carbone PP, et al. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-895.
23. Björkholm M, Holm G, Mellstedt H, et al. Prognostic factors in Hodgkin's disease. I. Analysis of histopathology, stage distribution and results of therapy. Scand J Haematol. 1977;19(5):487-495. (Pubitemid 8238235)
24. Glimelius B, Kalkner M, Enblad G, et al. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group. Ann Oncol. 1994;5(9):809-816. (Pubitemid 24341873)
25. Glimelius B, Enblad G, Kälkner M, et al. for the Swedish Lymphoma Study Group. Treatment of Hodgkin's disease: The Swedish National Care Programme experience. Leuk Lymphoma. 1996;21(1-2):71-78. (Pubitemid 26059006)
26. Molin D, Enblad G, Gustavsson A, et al. Swedish National Care Programme; Swedish Lymphoma Study Group. Early and intermediate stage Hodgkin's lymphoma-report from the Swedish National Care Programme. Eur J Haematol. 2003;70(3):172-180. (Pubitemid 36606077)
27. Bonadonna G, Zucali R, Monfardini S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-259.
28. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478-1484.
29. Björkholm M, Axdorph U, Grimfors G, et al. Fixed versus response adapted MOPP/ABVD chemotherapy in Hodgkin's disease. Ann Oncol. 1995;6(9):895-899.
30. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
31. Amini RM, Enblad G, Gustavsson A, et al. Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: the Swedish National Health Care Programme experience. Eur J Haematol. 2000;65(6):379-389.
32. Enblad G, Gustavsson A, Sundström C, et al Swedish Lymphoma Study Group. Patients above sixty years of age with Hodgkin's lymphoma treated with a new strategy. Acta Oncol. 2002;41(7-8):659-667. (Pubitemid 36106211)
33. Carde P, Koscielny S, Franklin J, et al. Early response to chemotherapy: a surrogate for final out-come of Hodgkin's disease patients that should influence initial treatment length and intensity? Ann Oncol. 2002;13(suppl):86-91. (Pubitemid 34567408)
34. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998;16(12):3810-3821. (Pubitemid 29001534)
35. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73(1):47-56. (Pubitemid 19040952)
36. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-1054. (Pubitemid 23114397)
37. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with highdose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-2071. (Pubitemid 34680969)
38. Askergren J, Björkholm M, Holm G, et al. Prognostic effect of early diagnostic splenectomy in Hodgkin's disease: A randomized trial. Br J Cancer. 1980;42(2):284-291. (Pubitemid 10006010)
39. Askergren J, Björkholm M, Holm G, et al. Prognostic influence of early diagnostic splenectomy in Hodgkin's disease. A long-term follow-up. Acta Med Scand. 1986;219(3):315-322. (Pubitemid 16012370)
40. Guinee VF, Björkholm M, Monfardini S. Hodgkin's disease in the elderly. In: Mauch PM, Armitage JO, Diehl V, et al, eds. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:713-725.
41. Landgren O, Algernon C, Axdorph U, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88(4):438-444. (Pubitemid 36547130)
42. Raud CG, Enblad G, Melin B, et al. Evaluation of the Nordic study for early stage Hodgkin lymphoma [abstract]. Ann Oncol. 2011;22(suppl 4):284.
43. Henson DE, Ries LA, The relative survival rate. Cancer. 1995;76(10):1687-1688.
44. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260(2):103-117. (Pubitemid 44051335)
45. Ederer F. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No 10, End Results Evaluation Section. Bethesda, MD: National Cancer Institute; 1959.
46. Dickman PW, Sloggett A, Hills M, et al. Regression models for relative survival. Stat Med. 2004;23(1):51-64. (Pubitemid 38072106)
47. Björkholm M, Svedmyr E, Sjöberg J. How we treat elderly patients with Hodgkin lymphoma. Curr Opin Oncol. 2011;23(5):421-428.
48. Brenner H, Gondos A, Pulte D. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008;111(6):2977-2983.
49. Longo DL. Late effects from radiation therapy: The hits just keep on coming. J Natl Cancer Inst. 2009;101(13):904-905.
50. Hjalgrim H, Askling J, Pukkala E, et al. Incidence of Hodgkin's disease in Nordic countries. Lancet. 2001;358(9278):297-298. (Pubitemid 32738971)
51. Mueller NE, Grufferman S. The epidemiology of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, et al, eds. Hodgkin's Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:61-77.